Concentrix (NASDAQ:CNXC) Trading Up 10.2% – Should You Buy?

Shares of Concentrix Corporation (NASDAQ:CNXC) were up 10.2% during trading on Thursday . The stock traded as high as $34.65 and last traded at $34.4390. Approximately 314,794 shares were traded during trading, a decline of 76% from the average daily volume of 1,326,616 shares. The stock had previously closed at $31.24.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on CNXC shares. Robert W. Baird set a $52.00 target price on shares of Concentrix in a research note on Wednesday, January 14th. Weiss Ratings lowered shares of Concentrix from a “hold (c-)” rating to a “sell (d)” rating in a report on Thursday, January 29th. Wall Street Zen raised Concentrix from a “hold” rating to a “buy” rating in a research report on Saturday, February 14th. Finally, Barrington Research reissued an “outperform” rating and issued a $62.00 target price on shares of Concentrix in a report on Monday, January 12th. Three research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $63.75.

Concentrix Stock Up 2.3%

The company has a market cap of $2.01 billion, a P/E ratio of -1.57, a price-to-earnings-growth ratio of 0.34 and a beta of 0.50. The company has a quick ratio of 1.40, a current ratio of 1.40 and a debt-to-equity ratio of 1.67. The company has a fifty day moving average of $38.61 and a 200 day moving average of $42.62.

Concentrix (NASDAQ:CNXC) last announced its earnings results on Tuesday, January 13th. The company reported $2.95 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.93 by $0.02. Concentrix had a positive return on equity of 16.91% and a negative net margin of 13.02%.The business had revenue of $2.55 billion for the quarter, compared to analysts’ expectations of $2.54 billion. During the same period last year, the firm posted $3.26 earnings per share. The business’s revenue for the quarter was up 4.3% on a year-over-year basis. Concentrix has set its Q1 2026 guidance at 2.570-2.690 EPS and its FY 2026 guidance at 11.480-12.070 EPS. On average, research analysts anticipate that Concentrix Corporation will post 10.11 earnings per share for the current fiscal year.

Concentrix Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Tuesday, February 10th. Shareholders of record on Friday, January 30th were issued a dividend of $0.36 per share. This represents a $1.44 dividend on an annualized basis and a yield of 4.4%. The ex-dividend date of this dividend was Friday, January 30th. Concentrix’s dividend payout ratio is currently -6.91%.

Insider Buying and Selling at Concentrix

In other Concentrix news, CEO Christopher A. Caldwell acquired 1,000 shares of the business’s stock in a transaction dated Thursday, January 29th. The stock was purchased at an average price of $37.07 per share, with a total value of $37,070.00. Following the transaction, the chief executive officer directly owned 362,075 shares in the company, valued at approximately $13,422,120.25. The trade was a 0.28% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 0.90% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Concentrix

Several institutional investors and hedge funds have recently bought and sold shares of CNXC. Royal Bank of Canada increased its position in Concentrix by 9.5% in the first quarter. Royal Bank of Canada now owns 47,501 shares of the company’s stock worth $2,643,000 after buying an additional 4,133 shares in the last quarter. Goldman Sachs Group Inc. grew its stake in shares of Concentrix by 75.1% during the 1st quarter. Goldman Sachs Group Inc. now owns 423,287 shares of the company’s stock valued at $23,552,000 after acquiring an additional 181,546 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its stake in shares of Concentrix by 17.4% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 146,515 shares of the company’s stock valued at $8,152,000 after acquiring an additional 21,746 shares during the period. Focus Partners Wealth purchased a new stake in Concentrix in the 1st quarter worth approximately $781,000. Finally, Geneos Wealth Management Inc. lifted its holdings in Concentrix by 532.7% during the first quarter. Geneos Wealth Management Inc. now owns 620 shares of the company’s stock valued at $34,000 after purchasing an additional 522 shares in the last quarter. 90.34% of the stock is currently owned by hedge funds and other institutional investors.

About Concentrix

Concentrix Inc (NASDAQ: CNXC) is a global business services company specializing in customer engagement solutions and technology‐driven business process outsourcing. The firm’s offerings encompass customer care delivered across voice and digital channels, back‐office processing, analytics and consulting, and automated workflow management. By integrating proprietary platforms, strategic partnerships and advanced automation, Concentrix helps clients enhance customer experiences and streamline operations.

Its capabilities extend to digital marketing and technology implementation, leveraging artificial intelligence, machine learning and data analytics to optimize customer journeys.